Biofrontera, Inc. - BFRI Enterprise Value to Sales Volume

Biofrontera Inc. (BFRI) - corporate logo

Has the leader in photodynamic therapy for dermatology become an attractive asset? The enterprise value-to-revenue multiple provides the answer, where the value 312.27 reflects this status for Biofrontera Inc. (BFRI). Demand for skin cancer prevention makes the business resilient to crises; however, high marketing expenses and challenges with insurance reimbursement in the US are putting pressure on the bottom line.

Biofrontera Inc - BFRI Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/19/2026)

Financial and market metric breakdowns for Biofrontera Inc (BFRI)

Fundamental company valuation:BFRI, Biofrontera Inc
Finished products of Biofrontera, Inc.

Biofrontera Inc. occupies a niche in high-tech treatment of precancerous skin lesions by supplying photodynamic therapy systems to US clinics. An analysis of EV/Sales history allows for an assessment of the business value, net of debt, relative to Ameluz sales volumes, where low values may signal undervalued assets and sharp spikes may indicate a market reassessment of the company's fundamental stability.